drugset
Drugs / CHT101
last change Mar 2026 re-read 3 minutes ago

CHT101

Cell therapy targets CD70

Developed for
brain cancer · cervical cancer · head and neck squamous cell carcinoma · metastatic neoplasm · nasopharyngeal carcinoma · ovarian cancer · peripheral T-cell lymphoma, not otherwise specified · primary cutaneous T-cell lymphoma
+3 more · refractory malignant neoplasm · renal cell carcinoma · systemic lupus erythematosus
Investigated by
Tianjin Medical University Cancer Institute and Hospital · Nanjing Calmhome Cell and Gene Engineering Institute Co., Ltd. · Nanjing Miracle Biotech Co. Ltd. · The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · Zhejiang University

Trials 5

today NCT07496073 · Ph 1 NCT06946485 · Ph 0 NCT06914037 · Ph 1 NCT06383507 · Ph 1 NCT06730659 · Ph 1
2025202620272028
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 01 trial
Phase 0 NCT06946485 Apr 2025 → Mar 2027 expected systemic lupus erythematosus The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School Recruiting No outcome recorded
Phase 14 trials
Phase 1 NCT07496073 Mar 2026 → Mar 2028 expected brain cancer Tianjin Medical University Cancer Institute and Hospital Not yet recruiting No outcome recorded
Phase 1 NCT06914037 Mar 2025 → Mar 2028 expected peripheral T-cell lymphoma, not otherwise specified, primary cutaneous T-cell lymphoma Tianjin Medical University Cancer Institute and Hospital Recruiting No outcome recorded
Phase 1 NCT06383507 Apr 2024 → Apr 2027 expected cervical cancer, head and neck squamous cell carcinoma, metastatic neoplasm, nasopharyngeal carcinoma +2 Zhejiang University Not yet recruiting No outcome recorded
Phase 1 NCT06730659 Apr 2024 → Apr 2027 expected refractory malignant neoplasm Tianjin Medical University Cancer Institute and Hospital Recruiting No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 5 sources stand behind the page.

FieldValueCited text
Known as CHT101 “CHT101 is an allogeneic CD70-targeted chimeric antigen receptor Tcell therapy, intended to be administered locally for the treatment of primary malignant brain tumors.” NCT07496073 ↗
4

NCT06730659 ↗

NCT06946485 ↗

NCT06914037 ↗

NCT06383507 ↗
Modality Cell therapy “CD70 UCAR T cells were transfused intravenously.” NCT06383507 ↗
Route Intravenous “transfused intravenously” NCT06383507 ↗
Target CD70 “CD70-targeted CAR-T” NCT06383507 ↗